INBX · Inhibrx Biosciences, Inc.

💊 Upcoming FDA Decisions

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →

📣 What INBX Says Is Next

• mid-2027 · INBRX-106: “The Company is currently conducting a Phase 1/2 study of INBRX-106 in the perioperative setting of non-small cell lung cancer (NSCLC), with initial results targeted by mid-2027.”
  Company press release, Sep 8, 2026 · SEC filing
• fourth quarter of 2026 · Ozekibart: “The Company plans to meet with the FDA in the fourth quarter of 2026 to discuss plans to initiate a first-line registrational trial in CRC as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC.”
  Company press release, Aug 13, 2026 · SEC filing
• first quarter of 2027 · Ozekibart: “The Company expects to announce interim results from these cohorts during the first quarter of 2027.”
  Company press release, Aug 13, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Dec 2028 · Phase 1 · Recruiting · Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors In
  Registry primary completion date, not a results date
• May 2029 · Phase 2/3 · Active Trial · INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
  Registry primary completion date, not a results date
• Sep 2025 · Phase 2 · Active Trial · Study of INBRX-109 in Conventional Chondrosarcoma
  Registry date passed, readout not confirmed

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not INBX's own candidates): Pembrolizumab, Cisplatin, Paclitaxel, Gemcitabine Hydrochloride, Pemetrexed Disodium, Temozolomide, Bevacizumab, Leucovorin, Fluorouracil, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INBX holds $133.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $34M/quarter from operations, an estimated runway of 11.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 20 · Moderate

• Cash runway 12 months +30
• Raised after last reported balance sheet (Jul 2026) -10

Recent financing filings on SEC EDGAR:

• Jul 16, 2026 · Private placement (8-K Item 3.02) · 8-K
• Jan 13, 2025 · Private placement (8-K Item 3.02) · 8-K
• May 30, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INBX files for a raise →

👥 Who Owns INBX

Share count 14,717,660 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.